Departed
Bruce Cassidy
director
OGEN ·
ORAGENICS INC
On January 15, 2025, Mr. Bruce Cassidy resigned as director of the Company to pursue other opportunities.
Ready 8-Ks
50
Latest filing
July 6, 2026, 4:05 PM ET
Top materiality
0.75
Event mix
other_material ×31 · leadership ×9 · other ×7
Sentiment
17 pos · 3 neg · 30 neu
Executive change
recent →
Recent 8-K filings for OGEN
Highest-materiality recent filing
Oragenics dosed first patient in Phase IIa concussion trial; signs LOI for CNS device
- Phase IIa trial of ONP-002 in Australia active; first patient dosed at Mackay Base Hospital March 2026.
- Signed LOI to license a complementary CNS medical device; expands addressable indication set beyond ONP-002.
-
Oragenics appoints John Spencer as CFO; shareholders authorize reverse stock split
John Spencer appointed CFO effective July 1, 2026; base salary $200,000, option award of $25,000.
-
Oragenics dosed first patient in Phase IIa concussion trial; signs LOI for CNS device
Phase IIa trial of ONP-002 in Australia active; first patient dosed at Mackay Base Hospital March 2026.
-
Oragenics signs LOI to license CardioDialysis from Sigyn Therapeutics for TBI
LOI grants Oragenics exclusive license for CardioDialysis blood purification tech in TBI and chronic neurodegenerative diseases.
-
Oragenics dosed first patient in Phase IIa trial of ONP-002 for mild traumatic brain injury
First patient dosed at Mackay Hospital (Australia) days after site activation on March 31, 2026.
-
Board scheduled 2025 Annual Meeting for June 29, 2026, more than 30 days from 2024 meeting anniversary.
-
Received final HREC approval in Australia for Phase IIa trial of ONP-002 for concussion/mTBI.
-
Oragenics extends ATM equity distribution agreement with Dawson James
On January 22, 2026, Oragenics amended its at-the-market sales agreement with Dawson James Securities.
-
Oragenics CEO presents at Sequire Investor Summit; filing lacks specific financial data
CEO presented at Sequire Investor Summit on January 20, 2026, using a new corporate presentation.
-
Oragenics board boosts CEO salary 5% to $341,250, awards bonus and options
CEO Janet Huffman base salary increased 5% from $325,000 to $341,250 effective Jan 1, 2026.
-
Regained NYSE American compliance on Oct 20, 2025, resolving equity deficiency and removing below-compliance indicator.
-
Oragenics settles Ladenburg dispute for $700K; regains NYSE American compliance
Paid $700K to Ladenburg Thalmann to settle $2.5M fee dispute; mutual release and arbitration dismissal.
-
Oragenics appoints Natasha Giordano to board of directors effective Sept 1, 2025
Natasha Giordano appointed to Oragenics Board effective September 1, 2025.
-
Oragenics raises $16.5M, advances ONP-002 Phase IIa concussion trial for Q3 2025
Raised $16.5M via Series H Preferred Stock and Warrants; net proceeds ~$15.2M after fees.
-
Oragenics closes $16.5M public offering of Series H Preferred Stock and Warrants
Issued 660,000 shares of Series H Convertible Preferred Stock at $25/unit with warrants to buy 660,000 additional shares.
-
Oragenics approves 1-for-30 reverse stock split to meet NYSE American listing standards
Reverse stock split at 1-for-30 ratio; effective 12:01 a.m. ET on June 3, 2025.
-
Oragenics furnishes Neurotrauma Medicine presentation; no specifics disclosed
Presentation on Neurotrauma Medicine provided for Scientific Advisory Board webinar on May 20, 2025.
-
Janet Huffman, previously CFO and Interim CEO, appointed permanent CEO effective May 2, 2025 under one-year agreement.
-
Oragenics submits Phase II concussion trial protocol to NZ ethics committee
Submitted clinical trial protocol to Health and Disability Ethics Committee (HDEC) in New Zealand for Phase II trial of ONP-002 for mild traumatic brain injury.
-
Oragenics Q1 update: $5M raised, ONP-002 Phase IIa trial advances
Raised ~$2.6M via ATM equity and ~$2.25M via non-dilutive debt; submitted DoD grant for concussion program.
-
Oragenics submits Investigator's Brochure for Phase II trial of ONP-002 in Australia
Phase II trial of intranasal neurosteroid ONP-002 for mild traumatic brain injury (mTBI); up to 40 participants enrolled across two arms.
-
Oragenics sets 2024 Annual Meeting for May 16, 2025; shareholder proposal deadline March 14
Board scheduled 2024 Annual Meeting for May 16, 2025, over 30 days later than 2023 meeting anniversary.
-
Oragenics CMO Dr. James Kelly to speak at 12th Annual Brain Health Summit on Feb 8, 2025
Dr. James P. Kelly, Oragenics CMO, will be a featured panelist at the 12th Annual Brain Health Summit on Feb 8, 2025 in New Orleans.
-
Oragenics appoints CFO Janet Huffman as interim CEO; provides ONP-002 Phase II timeline
CFO Janet Huffman named interim CEO, retaining CFO role; board expresses confidence in her leadership.
-
Oragenics names CFO Janet Huffman Interim CEO at $275K salary; director resigns
Janet Huffman appointed Interim CEO effective Jan 16, 2025; salary increased 10% to $275,000 with $75,000 cash bonus.
-
J. Michael Redmond terminated as Interim CEO/President effective Dec 16, 2024; CFO Janet Huffman appointed as new Interim CEO and President.
-
Oragenics notifies President J. Michael Redmond of non-renewal of employment agreement
Company gave non-renewal notice on Nov 26, 2024, for Employment Agreement dated Dec 28, 2023.
-
Oragenics President to present at Centurion One Capital Bahamas Summit on Oct 22, 2024
President Michael Redmond will present and host a Q&A at the summit on October 22, 2024 at 1:20 p.m. ET.
-
Oragenics files 8-K to furnish investor presentation; no specifics provided in filing text.
Company filed Form 8-K under Item 7.01 for Regulation FD disclosure of a presentation.
-
Oragenics enters $10M ATM stock offering agreement with Dawson James
May sell up to $10M common shares at-the-market through Dawson James Securities.
-
Oragenics updates on concussion drug ONP-002 progress; Phase II trial preparation advanced
ONP-002 cleared FDA cardiotoxicity and genotoxicity tests; spray-dry formulation completed with 4-fold drug increase per dose.
-
Oragenics awards stock options to executives; reschedules annual meeting to Dec 11, 2024
Compensation Committee approved immediate-vesting stock options: 100k shares to President Redmond, 80k to CFO Huffman.
-
Oragenics raises $4.45M in public offering; sold shares and pre-funded warrants at $0.55
Gross proceeds of ~$4.45M from offering of 3,078,378 shares and 5,028,206 pre-funded warrants.
-
Oragenics completes spray-dry manufacturing of ONP-002 for Phase IIa concussion trial
ONP-002 produced as spray-dried nanoparticle powder and filled in Oragenics' breath-propelled intranasal device.
-
Oragenics receives NYSE delisting notice for equity shortfall; ONP-002 Phase 2 trial planned Q4 2024
NYSE American notified Oragenics it is not in compliance with Section 1003(a)(i) (stockholders' equity <$2M); compliance plan approved, deadline Oct 18, 2025.
-
ONP-002 shows >99% purity after 3-month stability testing at -20°C to 104°C.
-
Oragenics: concussion drug ONP-002 shows no genotoxicity in animal study; Phase II planned
ONP-002 completed in vivo micronucleus assay; no evidence of genetic mutations or DNA damage across low, medium, high doses.
-
Oragenics' concussion drug ONP-002 passes FDA cardiotoxicity test, Phase II planned
ONP-002 showed no cardiotoxicity in GLP hERG study conducted by Charles River Laboratories.
-
Oragenics postpones 2023 Annual Meeting previously set for Aug 26, 2024
Board postponed the Aug 26, 2024 meeting; new date to be announced.
-
Oragenics develops improved intranasal formulation for concussion drug ONP-002
New formulation of ONP-002 designed to enhance brain uptake via nasal cavity, potentially reducing concussion symptoms.
-
Oragenics closes public offering of 1.1M shares at $1.00, raising $1.1M gross
Offering of 1,100,000 common shares at $1.00 per share closed on June 26, 2024.
-
NYSE American accepted Oragenics' plan to regain compliance with continued listing standards by October 18, 2025.
-
Annual Meeting rescheduled from July 15, 2024 to August 26, 2024.
-
Oragenics appoints Dr. William Peacock as Chief Clinical Officer for Phase II concussion trial
Appointed Dr. William 'Frank' Peacock as Chief Clinical Officer effective May 22, 2024.
-
Oragenics to host Neurotrauma Medicine webinar; will present ONP-002 mTBI update
Webinar scheduled for May 20, 2024, at 12:00 PM ET.
-
Oragenics preparing Phase II trial for concussion drug ONP-002; secures CRO, optimizes formulation
ONP-002 intranasal neurosteroid for mild TBI (concussion) advances to Phase II after positive Phase I safety.
-
Oragenics partners with Avance Clinical for Phase II concussion trial of ONP-002 in Australia
Phase II trial to evaluate ONP-002 for mild traumatic brain injury (concussion) delivered intranasally.
-
Oragenics receives NYSE American noncompliance notice; equity $3.2M below $4M/$6M thresholds
NYSE American notified Oragenics it fails continued listing standards due to stockholders' equity of $3.2M as of Dec 31, 2023.
-
Oragenics sets 2023 Annual Meeting for July 15, 2024; new shareholder proposal deadline May 20
Board established July 15, 2024 as date for 2023 Annual Meeting, moved more than 30 days from 2022 meeting anniversary.
-
Oragenics appoints Dr. James Kelly as CMO to lead Phase II concussion trial
Dr. Kelly will serve as CMO under an independent contractor agreement at $400/hour for 20 hours/month.
-
Oragenics closes $2.1M public offering of 1.4M shares; funds ONP-002 development
Issued 1,400,000 shares at $1.50/share for gross proceeds of $2.1M.
Executive changes
Appointed
(interim)
Michael Redmond
Interim Principal Executive Officer
OGEN ·
ORAGENICS INC
In addition, effective February 12, 2024, the Board appointed Michael Redmond, the Company’s President, as the Company’s Interim Principal Executive Officer.
Role change
(interim)
Charlie Pope
Executive Chairman
OGEN ·
ORAGENICS INC
The Board will provide direction to the Company during this transition in management, with Charlie Pope, the Company’s Chairman of the Board, serving, on an interim basis, as Executive Chairman, effective immediately.
Departed
Kimberly Murphy
Chief Executive Officer
OGEN ·
ORAGENICS INC
On February 12, 2024, Oragenics, Inc. (the “Company”) and Kimberly Murphy, the Company’s Chief Executive Officer, entered into a mutually agreeable Separation Agreement (the “Separation Agreement”), pursuant to which Ms. Murphy’s employment with the Company terminated effective February 12, 2024.
Appointed
Joseph Michael Redmond
President
OGEN ·
ORAGENICS INC
the Company entered into an Executive Employment Agreement with Joseph Michael Redmond, pursuant to which he will serve as the President of the Company
Appointed
Bruce Cassidy
Director
OGEN ·
ORAGENICS INC
Following the increase in the size of the Company’s board of directors, the Board of Directors appointed Mr. Bruce Cassidy and Mr. John Gandolfo to the Company’s board.
Appointed
John Gandolfo
Director
OGEN ·
ORAGENICS INC
Following the increase in the size of the Company’s board of directors, the Board of Directors appointed Mr. Bruce Cassidy and Mr. John Gandolfo to the Company’s board.
Appointed
Janet Huffman
Chief Financial Officer
OGEN ·
ORAGENICS INC
announced that the Board of Directors approved the appointment of Janet Huffman, as the Company’s new Chief Financial Officer
Appointed
(interim)
Kimberly Murphy
Interim Chief Financial Officer, Secretary and Treasurer
OGEN ·
ORAGENICS INC
Effective December 15, 2022, Ms. Kimberly Murphy, the Company’s President and Chief Executive Officer, was appointed Interim Chief Financial Officer, Secretary and Treasurer of the Company
Departed
Michael Sullivan
Chief Financial Officer, Secretary and Treasurer
OGEN ·
ORAGENICS INC
Michael Sullivan’s resignation as Chief Financial Officer, Secretary and Treasurer of the Company, to be effective December 14, 2022
Departed
Michael Sullivan
Chief Financial Officer
OGEN ·
ORAGENICS INC
On November 16, 2022, Michael Sullivan, the Chief Financial Officer of Oragenics (the “Company”) notified the Company that he would be resigning from the Company, effective December 14, 2022, to pursue other opportunities.
Appointed
Kimberly Murphy
President and Chief Executive Officer
OGEN ·
ORAGENICS INC
On June 23, 2022, Oragenics Inc. (the “Company”) announced that the Board of Directors approved the appointment of Kimberly Murphy, as the Company’s new President and Chief Executive Officer of the Company.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.57 · Most common event other_material